Observational Study of Clinical Performance of a Sterile, Bacteria-binding, Super-absorbent Wound Dressing
Study Details
Study Description
Brief Summary
This prospective, multicenter, single-arm observational study aims to document the clinical performance and safety of a sterile, bacteria-binding, super-absorbent wound dressing for the intended use in a daily clinical practice. 50 patients (male/female) with superficial wounds of any etiology affecting only epidermis and dermis layer, with one or more clinical signs of infection or at high risk of infection and also high to very high exudate levels will be observed over a period of 14 days.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with superficial wounds A cohort of 50 patients with superficial wounds of any etiology (see inclusion criteria), who need advanced wound care treatment in any case, will be observed over a period of 14 days; the exact duration for each patient depends upon the investigator's assessment. The observation consists of an initial visit, at least one dressing change after max. 7 days and a final visit. Patients will be treated with the CE-marked wound care product. This product is already in general use in the Netherlands and Germany. It is a sterile, bacteria-binding, super-absorbent wound dressing. Apart from the predefined study visits, daily dressing changes in accordance with daily clinical practice are possible. |
Outcome Measures
Primary Outcome Measures
- Number of patients with persisting infections will be documented in a standardized Case Report Form (CRF). [14 days]
Symptoms such as odor, pain, localized heat and erythema will be assessed by a clinician and documented in four different categories depending on its severity.
- Number of participants with newly developed infections will be documented in a standardized Case Report Form (CRF) [14 days]
Symptoms such as odor, pain, localized heat and erythema will be assessed by a clinician and documented in four different categories depending on its severity.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Men and women ≥ 18 years old
-
Written informed consent after patient education to participate in the study
-
Superficial wounds of any etiology affecting only epidermis and dermis layers
-
Maximum wound size: 6 x 16cm / 6 x 6cm
-
Wounds with one or more clinical signs or infection or assessed as at high risk of infection according to the following:
-
Wounds assessed as critically colonized with malodour, abnormal tissue or absence of viable tissue, excessive or increased serous exudate, possible extension of wound dimensions and no sign of a healing process and/or
-
Wounds with one or more historical episodes of topical infection and/or
-
Wounds assessed as at a high risk of infection on other grounds by the investigator.
-
Superficial wounds with high levels of exudate
Exclusion Criteria:
-
Not willing to sign or incapable of signing an informed consent form
-
Known allergy or sensitivity to one of the dressing components
-
Pregnancy or lactation
-
Subject is participating in another clinical study
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Welsh Wound Innovation Centre | Ynysmaerdy | Rhondda Cynon Taf | United Kingdom | CF728UX |
Sponsors and Collaborators
- BSN Medical GmbH
Investigators
- Principal Investigator: Nicky Ivins, Welsh Wound Innovation Centre
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- C1438